BR0017318A - Especificidade beneficiada no tratamento de doenças - Google Patents

Especificidade beneficiada no tratamento de doenças

Info

Publication number
BR0017318A
BR0017318A BR0017318-5A BR0017318A BR0017318A BR 0017318 A BR0017318 A BR 0017318A BR 0017318 A BR0017318 A BR 0017318A BR 0017318 A BR0017318 A BR 0017318A
Authority
BR
Brazil
Prior art keywords
drug
blocking group
reducing
benefited
specificity
Prior art date
Application number
BR0017318-5A
Other languages
English (en)
Inventor
Johnson Lau
Zhi Hong
Chin-Chung Lin
Original Assignee
Ribapharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribapharm Inc filed Critical Ribapharm Inc
Publication of BR0017318A publication Critical patent/BR0017318A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/052—Imidazole radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"ESPECIFICIDADE BENEFICIADA NO TRATAMENTO DE DOENçAS". Modificação de uma droga por acoplamento covalente de um grupo bloqueador à droga via um átomo de nitrogênio no grupo bloqueador. O grupo bloqueador na droga modificada previne a conversão metabólica e seq³estro da droga nas células não-alvo, e o grupo bloqueador é enzimaticamente removido na célula alvo. Particularmente, considera-se as vantagens dos compostos e métodos apresentados na redução da citotoxicidade por inibição da conversão metabólica em metabólitos potencialmente citotóxicos, redução das dosagens de drogas reduzindo-se o seq³estro para as células não-alvo, e aumento da seletividade de uma droga.
BR0017318-5A 2000-08-22 2000-12-07 Especificidade beneficiada no tratamento de doenças BR0017318A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22687000P 2000-08-22 2000-08-22
US22687100P 2000-08-22 2000-08-22
US22694800P 2000-08-22 2000-08-22
PCT/US2000/033454 WO2002016382A1 (en) 2000-08-22 2000-12-07 Improved specificity in treatment of diseases

Publications (1)

Publication Number Publication Date
BR0017318A true BR0017318A (pt) 2004-06-15

Family

ID=27397667

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0017318-5A BR0017318A (pt) 2000-08-22 2000-12-07 Especificidade beneficiada no tratamento de doenças

Country Status (15)

Country Link
EP (1) EP1351966A1 (pt)
JP (1) JP2004518618A (pt)
KR (1) KR20030040415A (pt)
CN (1) CN1460109A (pt)
AU (1) AU2001220806A1 (pt)
BR (1) BR0017318A (pt)
CA (1) CA2416748A1 (pt)
CZ (1) CZ2003460A3 (pt)
HU (1) HUP0302882A3 (pt)
IL (1) IL154168A0 (pt)
MX (1) MXPA03001528A (pt)
NO (1) NO20030762L (pt)
PL (1) PL365879A1 (pt)
TW (1) TW200414903A (pt)
WO (1) WO2002016382A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE457716T1 (de) 2002-12-30 2010-03-15 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
CN100448879C (zh) * 2004-07-22 2009-01-07 北京化工大学 一种无定型头孢呋辛酯的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991078A (en) * 1971-06-01 1976-11-09 Icn Pharmaceuticals, Inc. N-substituted 1,2,4-triazoles
US3984396A (en) * 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US3798209A (en) * 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
USRE29835E (en) * 1971-06-01 1978-11-14 Icn Pharmaceuticals 1,2,4-Triazole nucleosides
US4093624A (en) * 1977-01-31 1978-06-06 Icn Pharmaceuticals, Inc. 1,2,4-Thiadiazolidine-3,5-dione
JPS6426593A (en) * 1987-07-21 1989-01-27 Asahi Glass Co Ltd Nucleoside derivative
US4925930A (en) * 1988-11-02 1990-05-15 Nucleic Acid Research Institute Synthesis and anti-leukemic activity of alkyl-1-(β-D-ribofuranosyl)[1,2,4]triazole-3-carboximidates

Also Published As

Publication number Publication date
CZ2003460A3 (cs) 2003-10-15
TW200414903A (en) 2004-08-16
AU2001220806A1 (en) 2002-03-04
WO2002016382A1 (en) 2002-02-28
HUP0302882A2 (hu) 2003-12-29
CA2416748A1 (en) 2002-02-28
EP1351966A1 (en) 2003-10-15
MXPA03001528A (es) 2004-04-02
NO20030762L (no) 2003-04-22
HUP0302882A3 (en) 2005-06-28
IL154168A0 (en) 2003-07-31
JP2004518618A (ja) 2004-06-24
KR20030040415A (ko) 2003-05-22
NO20030762D0 (no) 2003-02-18
PL365879A1 (en) 2005-01-10
CN1460109A (zh) 2003-12-03

Similar Documents

Publication Publication Date Title
DK1032376T3 (da) Anvendelse af benzhydrylsulfinylderivater til behandling af søvnighed af medicinal oprindelse
BR9814018A (pt) Derivados de tienopirimidina e tienopiridina úteis como agentes anticâncer
SE0001899D0 (sv) New compounds
BR9712523A (pt) Novos derivados de pirazol heterociclilmetil-substituìdos
BR0113710A (pt) Compostos, processo para a preparação e utilização dos mesmos, composição farmacêutica, processo para o tratamento e profilaxia de artrite, enfermidades cardiovasculares, diabetes, insuficiência renal, distúrbios alimentares e obesidade
BRPI0518266A2 (pt) medicamento oral de libertaÇço modificada de pelo menos um princÍpio ativo sob a forma multimicrocapsular
PT1404347E (pt) Nucleosidos 4'-substituidos para o tratamento de doencas mediadas pelo virus da hepatite c
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
BR0008280A (pt) Derivados de tioamida
BRPI0519351A2 (pt) medicamentos para o tratamento ou prevenÇço de doenÇas fibràticas
BRPI0411098A (pt) benzofuranocarboxamidas, com atividade pi3k, como agentes terapêuticos
BR0313727A (pt) Derivados de isoquinolina como inibidores de metaloproteinase da matriz
ATE305473T1 (de) Pdgf-rezeptor-kinase hemmende verbindungen, deren herstellung, reinigung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
BR9912218A (pt) Compostos obtidos de espécies de sálvia possuindo atividade antivirótica
BRPI0411092A (pt) benzo[b]tiofenos substituìdos com 3-arilsulfanila e com 3-heteroarilsulfanila como agentes terapêuticos
BR0011578A (pt) Utilização do s-enantiÈmero de citalopram para tratamento de distúrbio de ansiedade geral ou ataques de pânico
IL151669A0 (en) Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same
BR0017318A (pt) Especificidade beneficiada no tratamento de doenças
CA2203463A1 (fr) Nouveaux acides et esters de la diosmetine, et les compositions pharmaceutiques les contenant
BR0006301A (pt) Macrólidos antibacterianos e pró-cinéticos
FR2869904A1 (fr) Modulateurs des recepteurs lxr
BR0013306A (pt) Processos úteis na sìntese de compostos antipicornavirais
BR0013723A (pt) Uso de bissulfonamidas, para produção de medicamentos para profilaxia ou tratamento de hiperlipidemia
BRPI0408380A (pt) derivados 7-imino de camptotecina tendo atividade antitumoral
BRPI0414171A (pt) benzo[b]tiofenos halossubstituìdos com atividade inibidora de pi3k como agentes terapêuticos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1929 DE 26/12/2007.